Research Papers:
The association of the hepatitis B virus infection with thyroid carcinoma: a large sample clinical study in China
Metrics: PDF 317 views | HTML 767 views | ?
Abstract
Wei Dai1,*, Yu-Tuan Wu2,*, Xin Li2,*, Yan-Ling Shi2,*, Lu Gan3, Hong-Yuan Li2, Guo-Sheng Ren2, Kai-Nan Wu2 and Ling-Quan Kong2
1Department of Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
2Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
3Department of Oncology and Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
*These authors contributed equally to this work
Correspondence to:
Ling-Quan Kong, email: [email protected]
Keywords: hepatitis B core antibody; hepatitis B virus; past infection; thyroid carcinoma; thyroid stimulating hormone
Received: July 12, 2017 Accepted: December 05, 2017 Published: January 02, 2018
ABSTRACT
Objective: To explore whether thyroid carcinoma is associated with the infection of hepatitis B virus.
Results: Although there were no differences on the positive rates of Hepatitis B surface antigen and hepatitis B surface antibody in the thyroid carcinomas group (8.67% & 59.24%) and control group (8.86% & 58.21%, p > 0.05), the positive rate of hepatitis B core antibody in thyroid carcinomas group (55.71%) was significantly lower than that in the control group (63.28%, p = 0.0004). Through the logistic regression analysis, compared to the control group, the rate of hepatitis B core antibody seropositivity was lower in thyroid carcinomas group in whole cases (Adjusted OR = 0.82, 95% CI 0.69–0.98, p = 0.0337). In addition, compared to the control group, a more interesting result was found that the adjusted OR value of hepatitis B core antibody seropositivity of male is lower than female in statistics (Adjusted OR = 0.62, 95% CI 0.41–0.94, p = 0.0237; Adjusted OR = 0.89, 95% CI 0.72–1.08, p > 0.05, respectively).
Conclusions: The rate of hepatitis B core antibody seropositivity in thyroid carcinoma patients is lower than that in controls and the past hepatitis B virus infection may be a weak protective factor for the development of thyroid carcinoma.
Methods: In this study, the clinical data of 2134 patients with initially diagnosis of thyroid nodules while receiving surgery, with the reports of hepatitis B virus serological markers in single center from June 2010 to September 2015, were collected for comparative analysis. Of all there were 1050 (49.20%) cases of thyroid carcinomas group and 1084 (50.80%) noncancerous thyroid nodules group.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23712